Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratorios liconsa s.a. - venlafaxinhydrochlorid - depottabletter - 150 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratorios liconsa s.a. - venlafaxinhydrochlorid - depottabletter - 225 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratorios liconsa s.a. - venlafaxinhydrochlorid - depottabletter - 75 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatiske neoplasmer - endokrine terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - mycophenolatnatrium - enterotabletter - 180 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - mycophenolatnatrium - enterotabletter - 360 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - corifollitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - køn hormoner og modulatorer af den genitale system, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).